Stock Analysis
IQVIA Holdings Inc.IQV
P/E 31.95×· 5Y range 18.22–84.21×· 50th percentile of history
Sector: Healthcare · Industry: Services-Commercial Physical & Biological Research
AnalystsStrong Buy28 analystsP/E 32.0× sits at the 50th percentile of its 5.086926762491444-year history.
Cash covers 15% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality90
- Growth63
Risks
- Financial Health39
Mixed picture — no clear quality or value edge.
Bull Case
- ✓ROE 21.1% — efficient capital deployment
What's happening with IQV
Profile
Strong earnings quality; moat, financial health and valuation lag behind.
How is each axis scored?
- Valuation49/100 · Weak
- P/E vs own history (50th pct)12/25
- FCF yield (5.0%)12/25
- P/S (2.6x)20/25
- EV/EBIT (25.3x)5/25
- Growth63/100 · Moderate
- Revenue CAGR (4.1%)6/25
- Net income CAGR (8.9%)12/25
- EPS CAGR 5Y (12.2%)20/25
- Fwd implied growth (54.9%)25/25
- Profitability57/100 · Moderate
- ROIC (9.5%)12/25
- ROE (21.1%)20/25
- Net margin (8.1%)13/25
- Operating margin (13.0%)12/25
- Financial Health39/100 · Weak
- Altman Z (2.24)18/25
- Current ratio (0.75)6/25
- Interest coverage (2.6x)10/25
- Net cash / debt (D/A 39%)5/25
- Quality90/100 · Strong
- Piotroski F (5/9)15/25
- Beneish M (-2.59)25/25
- FCF conversion (159%)25/25
- Margin stability (σ 3.9%)25/25
- Moat37/100 · Weak
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 1.7%)12/25
Risk Flags
- ⚠Interest coverage 2.6× — thin debt cushion
About IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Show more
Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Headquarters: DURHAM, NC · Employees: 94,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
49D+P/E (TTM)32.0xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 18.2x–84.2x · 50th pct
P/FCF20.3xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.0%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.7%–8.9% · 58th pct
P/S (TTM)2.59xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.6x–4.1x · 44th pct
EV/EBIT25.3xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 16.2x–55.6x · 42nd pct
EV/Sales3.4xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E20.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.76xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.00C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
57CROIC9.5%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE21.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA4.7%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin8.1%C
Grade C: AverageNet Income / Revenue
Operating Margin13.0%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin33.0%C
Grade C: AverageGross Profit / Revenue
FCF Margin12.9%C
Grade C: AverageFCF / Revenue
True FCF Margin11.2%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
63BRevenue CAGR4.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR8.9%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)12.2%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth54.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-15.5%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income20.0%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
39DAltman Z-Score2.24C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.75xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.68xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage2.6xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment5.4yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT5.3xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity2.14xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.15xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
90A+Piotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.59A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion158.8%A
Grade A: StrongFCF / Net Income
Margin Stability3.9%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.57xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Berkshire James G. Filed | Berkshire James G. | Option exercise | -5381 | |
Berkshire James G. Filed | Berkshire James G. | SellDisposition | -2713 | |
Berkshire James G. Filed | Berkshire James G. | SellOpen market sale | -2668 | |
Berkshire James G. Filed | Berkshire James G. | Option exercise | +5.4K | |
STAUB W RICHARD Filed | STAUB W RICHARD | SellOpen market sale | -5500 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Patel Bhavik Filed | Patel Bhavik | SellOpen market sale | -1855 | |
Sherbet Eric Filed | Sherbet Eric | SellOpen market sale | -5000 | |
Cherofsky Keriann Filed | Cherofsky Keriann | SellOpen market sale | -558 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
37DROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor1.7%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.35
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$12.64
Cash & short-term investments per share (Finnhub)
Book Value / Share$37.49
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$13.88B
Total debt obligations (short + long term)
Cash & Equiv.$2.14B
Cash and short-term investments
Net Debt$11.74B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$6.50B
Shareholders' equity (book value)
Asset / Liability1.28xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$43.93B
Current Market Capitalization
Beta1.18B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: IQVIA Holdings Inc. (IQV)
IQV is down 1.53% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for IQVIA Holdings Inc.. Altman Z-Score of 2.24 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -2.59 suggests a low likelihood of earnings manipulation.
- Takes ~5.4 years to repay net debt from free cash flow.
- Return on equity of 21.1% is well above the market average.
See how IQV ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all IQV moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 271.34 | +3.56% | 2.48 |
| Oct 15 | After-hours | 271.04 | +3.45% | 2.41 |
| Oct 5 | After-hours | 266.09 | +3.05% | 2.14 |
| Oct 1 | Regular | 260.92 | -2.95% | -2.06 |
Frequently Asked Questions about IQV
What is the current IQVIA Holdings Inc. (IQV) stock price?
IQV is trading at $266.90 at the last market close, down 1.53% on the session. PreMarketPrice tracks IQV pre-market, intraday and after-hours prices.
Is IQV stock a buy right now?
PreMarketPrice's quantitative model rates IQVIA Holdings Inc.'s financial health at 39/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is IQV stock overvalued?
IQVIA Holdings Inc. trades at a trailing P/E of 32.0 and our valuation score rates it 49/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does IQVIA Holdings Inc. report earnings?
No confirmed earnings date is currently scheduled for IQV. The Earnings section lists recent reports and updates as dates are announced.
What sector does IQVIA Holdings Inc. operate in?
IQVIA Holdings Inc. operates in the Healthcare sector, within the Services-Commercial Physical & Biological Research industry. The Related Stocks section lists sector peers for comparison.
What does IQVIA Holdings Inc. do?
Iqvia is a global leader in clinical research and technology solutions for the life science industry.
About IQVIA Holdings Inc. (IQV) Stock
IQVIA Holdings Inc. (IQV) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry. As of the latest update, IQVIA Holdings Inc. is trading at $266.90, down 1.53% on the day with a market capitalization of $43.9 billion. The financial health score for IQV is 39/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for IQV stock.
IQV Stock Analysis & Key Metrics
On PreMarketPrice, you can track IQVIA Holdings Inc. (IQV) across multiple dimensions:
- Pre-market price & movement: Real-time IQV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for IQV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for IQVIA Holdings Inc. across multiple reporting periods.
- Financial health score: A composite score of 39/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for IQV.
- Sector peers: Compare IQV against 6 other healthcare stocks on key financial metrics.
Is IQV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate IQVIA Holdings Inc. (IQV) as an investment. The financial health score of 39/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.IQVIA Holdings Inc. (IQV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.